Okay, let's tackle this question. The patient is a 50-year-old woman with cervical cancer stage II-III. The question is about the most appropriate next step in management. First, I need to recall the standard treatment protocols for cervical cancer based on staging.

Cervical cancer staging is crucial because treatment varies with the stage. Stage I is usually treated with surgery (like radical hysterectomy) or radiation. However, stages II to IV typically require more aggressive approaches. For stages II and III, the standard treatment is usually concurrent chemoradiotherapy. This combines external beam radiation therapy (EBRT) with brachytherapy and chemotherapy, often using cisplatin-based regimens. The chemotherapy enhances the effectiveness of radiation.

Looking at the options, the correct answer is likely to be concurrent chemoradiotherapy. Let's check the other options. Surgery might be considered in early stages, but not for II-III. Neoadjuvant chemotherapy alone isn't standard here. Radiation alone without chemotherapy isn't sufficient for these stages. So, the correct answer must be the combination therapy. The clinical pearl here is that concurrent chemo and radio is the gold standard for locally advanced cervical cancer. That's a high-yield fact for exams.

**Core Concept**
Cervical cancer staging (FIGO system) determines treatment strategy. Stages II-III involve locally advanced disease requiring multimodal therapy to balance tumor control and organ preservation. Concurrent chemoradiotherapy is the cornerstone for these stages due to its radiosensitizing effects.

**Why the Correct Answer is Right**
Concurrent chemoradiotherapy (CRT) with cisplatin-based chemotherapy enhances radiation efficacy by inducing tumor cell apoptosis and reducing hypoxia. This approach combines external beam radiation, brachytherapy, and intravenous cisplatin every 3-4 weeks. It is superior to radiotherapy alone in improving survival and local control for stages II-III cervical cancer, per NCCN and ESMO guidelines.

**Why Each Wrong Option is Incorrect**
**Option A:** Radical hysterectomy with lymph node dissection is reserved for early-stage (IA-IIA1) disease, not locally advanced stages.
**Option B:** Neoadjuvant chemotherapy alone lacks evidence for stages II-III; CRT remains the standard.
**Option D:** Radiation therapy alone (without chemotherapy) is less effective and associated with higher recurrence rates in advanced stages.

**Clinical Pearl / High-Yield Fact**
Never treat stages II-III cervical cancer with radiotherapy alone—**concurrent CRT is mandatory**. Remember the acronym **CIS** (Cisplatin) for the chemotherapy agent used in CRT, paired with **EBRT + brachytherapy**. This is a classic exam trap: students may confuse early-stage surgical options with advanced-stage protocols.

**Correct Answer: C. Concurrent chemoradiotherapy**

✓ Correct Answer: B. Radiotherapy and chemotherapy